RxDoctor Payments Data

Neil Jouvenat, PA

Physician Assistant · Omaha, NENPI 1003096710

Payments from drug & device makers

$3,641in general payments, 2019–2025

Across 45 payments — averaging $80.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • EMD Serono, Inc.$443
  • TG Therapeutics, Inc.$420
  • Sanofi$189
  • Biogen$183
  • Bristol Myers Squibb$153
  • plus $567 from 5 others

What the payments were for

  • Travel & lodging$1,28635%
  • Food & beverage$2,33364%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic18$1,687
EMD Serono, Inc.6$443
TG Therapeutics, Inc.4$420
Sanofi2$189
Biogen3$183
Bristol Myers Squibb4$153
Genentech USA, Inc.4$152
Amgen1$140
Piramal Critical Care1$120
AstraZeneca1$109
E.r. Squibb & Sons, L.L.C.1$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,641 in reported general payments places this provider in the 90th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$19,002
Medicare patients
108
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate82$466,951
Kesimpta PenOfatumumab44$368,086
Avonex Pen (4 Pack)Interferon Beta-1a38$302,780
Plegridy PenPeginterferon Beta-1a17$198,529
Glatiramer Acetate89$151,968
AubagioTeriflunomide14$128,743
FingolimodFingolimod Hcl25$94,686
Teriflunomide92$79,985
VumerityDiroximel Fumarate11$29,895
Emgality PenGalcanezumab-Gnlm35$22,550
Dalfampridine ErDalfampridine73$13,853
Dimethyl Fumarate35$5,955
BelsomraSuvorexant12$5,243
Baclofen126$2,855
Gabapentin77$2,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$189$128,74314 claims
BiogenVumerity$183$29,89511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →